At Dana-Farber Cancer Institute in Boston, researchers have completed a clinical trial showing that paricalcitol, a vitamin D analog already approved by the FDA for treating kidney disease, can safely dismantle the protective shield that allows pancreatic cancer to resist chemotherapy. The discovery emerged from a decade-long scientific journey that began with Ronald Evans' groundbreaking work on the vitamin D receptor—work that has fundamentally shaped how modern medicine approaches drug development, since approximately 13% of all FDA-approved drugs today work by targeting the same family of molecules he discovered.
Pancreatic cancer is one of medicine's most stubborn adversaries. The tumors are surrounded by activated fibroblasts—cells that form a dense, protective microenvironment capable of blocking chemotherapy and suppressing immune responses. This barrier, so fundamental to the disease's deadliness, became the focus of Evans' team at Salk Institute, who discovered through preclinical research that the vitamin D receptor regulates these fibroblasts. When they tested synthetic vitamin D analogs like paricalcitol on pancreatic cancer models, something remarkable happened: the drugs reversed the activation of cancer-associated fibroblasts, making the tumors more vulnerable to chemotherapy.
The randomized trial, led by Brian Wolpin and Kimberly Perez at Dana-Farber, tested this hypothesis in 36 patients with previously untreated metastatic pancreatic cancer. Participants received standard chemotherapy—gemcitabine plus nab-paclitaxel—with or without paricalcitol delivered either intravenously or orally. The study was not designed to measure treatment efficacy, but rather to establish safety and confirm that the approach reduced fibroblast activation in the tumor microenvironment, a finding that validated Salk's preclinical work.
What emerged from the data was even more encouraging. Patients who received paricalcitol alongside chemotherapy showed improved responses to the standard therapy and greater progression-free survival at one year compared to the control group. The most striking result came from patients with high vitamin D receptor expression who received paricalcitol: they experienced the longest overall survival times in the trial. The findings were published in Nature Cancer, drawing international attention from oncologists seeking new strategies against a cancer that kills approximately 47,000 Americans annually.
"This study really takes a novel approach to cracking therapeutic resistance in pancreatic cancer," Evans said in a statement. "By using vitamin D analogs to engage the body's own natural system for dampening fibrotic and inflammatory responses, we can enable other therapies to do their job." The approach represents a fundamental shift in pancreatic cancer treatment strategy—rather than simply attacking cancer cells more aggressively, it reprograms the tumor's environment to make it permeable to existing therapies.
Paricalcitol itself is not new; physicians have used it for years to prevent secondary hyperparathyroidism in chronic kidney disease patients. But this trial marks the first time its ability to reshape the pancreatic tumor microenvironment has been validated in human patients. The safety profile was reassuring, suggesting that future trials exploring paricalcitol's efficacy as part of a pancreatic cancer treatment regimen can move forward with confidence. For patients facing a diagnosis that remains one of oncology's greatest challenges, this small Boston trial offers a glimmer of possibility: that sometimes the most powerful new weapons come from repurposing tools already in medicine's hands.